Abstract
Epidermolysis bullosa (EB) is a group of inherited skin disorders characterized by extreme skin fragility, leading to recurrent blistering and significant impacts on patients' quality of life. A bibliometric analysis of the 50 most-cited EB articles from the past six decades reveals that the majority of research focuses on understanding EB pathogenesis, with a growing emphasis on therapeutic interventions, particularly gene and cell-based therapies. This study highlights a shift toward clinical trials in recent years, but there is still a need for more global collaboration to address regional variations in EB and improve treatment outcomes for patients worldwide.